BioSpace News Archive

Business

Mazor Robotics Reports Record Fourth Quarter & Full Year 2017 Financial Results

Revenue for the three months ended December 31, 2017 increased 36% to $19.1 million compared to $14.0 million in the year-ago fourth quarter.

February 14, 2018

·

26 min read

Drug Development

Mallinckrodt Enrolls First Patient in Phase I Study of ExpressGraft C9T1 Skin Tissue

The Phase 1 study is titled “ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers.""

February 14, 2018

·

6 min read

Business

Alkermes Reports Financial Results for the Year Ended Dec. 31, 2017 and Provides Financial Expectations for 2018

Alkermes today reported financial results for the twelve months ended Dec. 31, 2017 and provided financial expectations for 2018.

February 14, 2018

·

53 min read

BioMidwest

Cardiovascular Systems, Inc. Announces First Patients Treated from Radial Access Using Its Diamondback 360 Extended Length Peripheral Orbital Atherectomy Device

Cardiovascular Systems announced today that the first patients were treated using its FDA-cleared extended length Diamondback 360 Peripheral Orbital Atherectomy Device (OAD) to treat peripheral artery disease (PAD).

February 14, 2018

·

7 min read

Drug Development

Therachon Announces Dosing of First Subject in Phase I Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia

Therachon today announced the dosing of the first subject in its Phase 1 trial for TA-46, a soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) ligand trap.

February 14, 2018

·

3 min read

Pharm Country

Celgene Announces Additional $5B Share Repurchase Authorization

This open-ended program is effective immediately.

February 14, 2018

·

2 min read

Business

China Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2018 Financial Results

China Cord Blood Corporation today announced that it plans to release financial results for the third quarter and first nine months fiscal year 2018 on Monday, February 26, 2018, after the market close.

February 14, 2018

·

2 min read

Business

ImmunoQure AG and Servier Enter Into Strategic Partnership for the Development of an Interferon-Alpha Human Autoantibody

ImmunoQure and Servier will work collaboratively to advance ImmunoQure’s therapeutic human Interferon-alpha autoantibody through preclinical development and into the clinic.

February 14, 2018

·

4 min read

Policy

TransEnterix Announces FDA 510(k) Submission for Senhance Indication Expansion to More than Double Addressable Market in the U.S. and Provides Commercial Update

TransEnterix today announced the Company has filed a FDA 510(k) submission to expand the indication for use of its Senhance Surgical System, and provided an update about commercial results thus far for the quarter ending March 31, 2018.

February 14, 2018

·

4 min read

Policy

Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL Plaque Psoriasis Treatment

If approved, JEMDEL will be the first high-potency topical steroid treatment for plaque psoriasis with dosing for as long as eight weeks.

February 14, 2018

·

3 min read